Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

被引：0
|
作者：
Garcia-Manero, G.
Yang, A. S.
Klimek, V.
Luger, S.
Newsome, W. M.
Berman, N.
Patterson, T.
Maroun, C.
Li, Z.
Ward, R.
Martell, R.
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Norris Cromprenhens Canc Ctr, Los Angeles, CA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[5] MethylGene, Montreal, PQ, Canada
[6] Pharmion, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    Garcia-Manero, Guillermo
    Yang, Allen S.
    Giles, Francis
    Faderl, Stefan
    Ravandi, Farhad
    Cortes, Jorge
    Newsome, Willie M.
    Issa, Jean-Pierre
    Patterson, Tracy-Ann
    Dubay, Marja
    Li, Zuomei
    Kantarjian, Hagop
    Martell, Robert E.
    BLOOD, 2006, 108 (11) : 552A - 553A
  • [2] Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)
    DiPersio, John
    Stadtmauer, Edward A.
    Nademanee, Auaypom P.
    Stiff, Patrick
    Micallef, Ivana
    Angell, J.
    Bridger, G.
    Calandra, Gary
    BLOOD, 2007, 110 (11) : 137A - 137A
  • [3] Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors
    Hurwitz, H.
    Nelson, B.
    O'Dwyer, P. J.
    Chiorean, E. G.
    Gabrail, N.
    Li, Z.
    Laille, E.
    Drouin, M.
    Rothenberg, M. L.
    Chan, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)
    Luger, Selina M.
    O'Connell, Casey Lee
    Klimek, Virginia
    Cooper, Maureen A.
    Besa, Emmanuel C.
    Rossetti, James M.
    Reid, Gregory K.
    Humphrey, Rachel
    Martell, Robert E.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [6] Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors
    Hurwitz, Herbert I.
    Chan, Emily
    O'Dwyer, Peter
    Gabrail, Nashat
    Li, Zuomei
    Kalita, Ann
    Bourget, M. C. Trachy
    Tawashi, Manal
    Martell, R. E.
    Ward, R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3477S - 3477S
  • [7] Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.
    Carducci, M.
    Siu, L. L.
    Sullivan, R.
    Maclean, M.
    Kalita, A.
    Chen, E. X.
    Pili, R.
    Martell, R. E.
    Besterman, J.
    Reid, G. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 122S - 122S
  • [8] Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.
    Siu, LL
    Carducci, M
    Pearce, L
    Maclean, M
    Sullivan, R
    Li, ZM
    Kalita, A
    Chen, EX
    Pili, R
    Longstreth, J
    Martell, RE
    Reid, GK
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9118S - 9118S
  • [9] Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, Anas
    Wedgwood, Amanda
    McLaughlin, Peter
    Andreadis, Charalambos
    Assouline, Sarit E.
    Li, Zuomei
    Martell, Robert E.
    Dubay, Marja
    Patterson, Tracy-Ann
    Ward, Michelle R.
    Crump, Michael
    BLOOD, 2007, 110 (11) : 758A - 758A
  • [10] Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).
    Garcia-Manero, G.
    Minden, M.
    Estrov, Z.
    Verstovsek, S.
    Newsome, W. M.
    Reid, G.
    Besterman, J.
    Li, Z.
    Pearce, L.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S
12345